×

Immunomedics to Present Updated Clinical Trial Results for Antibody-Drug Conjugates at Cancer Conference

MORRIS PLAINS, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that two abstracts have been accepted for oral presentation in a Clinical Trials Minisymposium session at the 2016 American Association for Cancer Research (AACR) Annual Meeting. The first abstract is on Phase 2 results of sacituzumab govitecan (IMMU-132), the Company’s lead antibody-drug conjugate (ADC), in patients with metastatic urothelial cancer. Sacituzumab govitecan has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of patients with triple-negative breast cancer (TNBC) who have failed at least 2 prior therapies for metastatic disease.

In addition, updated results from a Phase 2 study of labetuzumab govitecan (IMMU-130), the Company’s anti-CEACAM5/SN-38 ADC, in patients with metastatic colorectal cancer also will be presented in the same Minisymposium session.

Finally, results from a preclinical study of sacituzumab govitecan demonstrating synergy with microtubule or poly (adenosine diphosphoribose) polymerase (PARP) inhibitors in various animal models of human TNBC, as well as a study undertaken to continue preclinical evaluations of IMMU-114, the Company’s proprietary humanized antibody that targets a human leukocyte transplantation antigen, or HLA-DR, comparing its efficacy to anti-CD20 or doxorubicin therapy, respectively, and in combination with kinase inhibitors, will be reported.

The AACR conference will be held at the Ernest N. Morial Convention Center in New Orleans, LA, from April 16 – 20, 2016. Details of the four presentations are listed below (all times are in Central Time):

Sunday, April 17, 2016

  • Significant enhancement of efficacy of an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), in experimental triple-negative breast cancer (TNBC) when combined with microtubule or PARP inhibitors (Cardillo, et al.)
    Poster Session: Therapeutic Antibodies, #27
    Abstract #584, Poster Board #15
    1:00 p.m. - 5:00 p.m.
    Halls G-J

  • Superior anti-tumor effects of an anti-HLA-DR IgG4 antibody, IMMU-114, in chronic and acute lymphocytic leukemia (CLL and ALL): Comparison to anti-CD20 therapy, chemotherapy, or combined with kinase inhibitors (Cardillo, et al.)
    Poster Session: Therapeutic Antibodies, #27
    Abstract #587, Poster Board #18
    1:00 p.m. - 5:00 p.m.
    Halls G-J

Monday, April 18, 2016

  • Treatment for metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience (Tagawa, et al.)
    Minisymposium: Early Clinical Trials of Novel Agents
    Abstract #CT064
    3:00 p.m. - 5:00 p.m.
    Room 391

  • Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results (Dotan, et al.)
    Minisymposium: Early Clinical Trials of Novel Agents
    Abstract #CT065
    3:00 p.m. - 5:00 p.m.
    Room 391

About Immunomedics
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics’ advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of eight clinical-stage product candidates. Immunomedics’ portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics’ most advanced ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. IMMU-132 has received Breakthrough Therapy Designation from FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease. Immunomedics has a research collaboration with Bayer to study epratuzumab as a thorium-227-labeled antibody. Immunomedics has other ongoing collaborations in oncology with independent cancer study groups. The IntreALL Inter-European study group is conducting a large, randomized Phase 3 trial combining epratuzumab with chemotherapy in children with relapsed acute lymphoblastic leukemia at clinical sites in Australia, Europe, and Israel. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and preclinical development. These include combination therapies involving its antibody-drug conjugates, bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 286 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. For additional information on the Company, please visit its website at www.immunomedics.com. The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, outcomes, timing or associated costs), out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirements/actions), the Company’s dependence on business collaborations in order to further develop our products and finance our operations, the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our drug candidates, risks associated with the outcome of pending litigation and competitive risks to marketed products, and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information:
Dr. Chau Cheng
Senior Director, Investor Relations & Corporate Secretary
(973) 605-8200, extension 123
ccheng@immunomedics.com

Source:Immunomedics